Cargando…

Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020

BACKGROUND: The Korean regulatory authority has enacted legislation to expedite the new drug approval (NDA) process. However, the effectiveness of such efforts in reducing review time and drug approval delays between Korea and the USA/EU remains to be evaluated. METHODS: We investigated NDA trends i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Hyeyoung, Lee, Hyesung, Park, Bojung, Kim, Chorong, Lee, Jaehyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133380/ https://www.ncbi.nlm.nih.gov/pubmed/36539577 http://dx.doi.org/10.1007/s43441-022-00486-x

Ejemplares similares

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations
por: Boesen, Kim, et al.
Publicado: (2021)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014–2016: Concordance, Discordance, and Why
por: Kashoki, Mwango, et al.
Publicado: (2019)

A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products
por: Muselík, Jan, et al.
Publicado: (2021)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
por: Hiayev, Stephany, et al.
Publicado: (2023)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
por: Thor, Shannon, et al.
Publicado: (2023)

Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States
por: Cho, Inhye, et al.
Publicado: (2022)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
por: Fortner, Andra, et al.
Publicado: (2021)

Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea
por: Lee, Munjae, et al.
Publicado: (2015)

Extensively Drug-Resistant Streptococcus pneumoniae, South Korea, 2011–2012
por: Cho, Sun Young, et al.
Publicado: (2014)

Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020)

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
por: Alidjanov, Jakhongir F., et al.
Publicado: (2019)

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
por: Hanaizi, Zahra, et al.
Publicado: (2022)

Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS
por: Kang, Su Lim, et al.
Publicado: (2023)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

EMA's CHMP meeting highlights from September 2020
Publicado: (2020)

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
por: Costa, Enrico, et al.
Publicado: (2022)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019)

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2020)

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2022)

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023)

Long-term sentinel surveillance of enteroviruses in Gwangju, South Korea, 2011–2020
por: Kim, Min Ji, et al.
Publicado: (2023)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Trends in National Pharmaceutical Expenditure in Korea during 2011 - 2020
por: Kim, Yujeong, et al.
Publicado: (2023)

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022)

A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children
por: Murano, Maria Cristina
Publicado: (2020)

Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0nui08o7cl4n8mlp2inauffgfm